Tessera (TSRA) Enters Patent License Agreements w/ SK hynix
Tweet
Share
E-mailGet Alerts TSRA Hot Sheet
Join SI Premium – FREE
Tessera Technologies, Inc. (NASDAQ: TSRA) announced that its Tessera, Inc. and Invensas Corporation subsidiaries each entered into new eight-year patent license agreements with SK hynix Inc.
“We are delighted that these new and broader agreements build on our long-standing and positive relationship with SK hynix, which has become the first DRAM manufacturer to reach agreements that give it access to both our Tessera, Inc. and our Invensas Corporation patent portfolios,” said Robert A. Young, chief executive officer and president, Tessera Technologies, Inc. “Multi-year agreements like these benefit our customers with secure pricing and provide us with running royalties that fund new innovations.”
The companies did not disclose the specific financial terms of the agreements, under which SK hynix will make a one-time payment and pay running royalties. The agreement will result in an increase in the Company’s recurring royalty revenues from SK hynix beginning in Q2 2013 because the Company reports royalties one quarter in arrears. The Company and SK hynix also agreed to dismiss the antitrust lawsuit pending in California state court. The Company is neither updating its financial guidance nor providing additional financial guidance in connection with this milestone.
“We are delighted that these new and broader agreements build on our long-standing and positive relationship with SK hynix, which has become the first DRAM manufacturer to reach agreements that give it access to both our Tessera, Inc. and our Invensas Corporation patent portfolios,” said Robert A. Young, chief executive officer and president, Tessera Technologies, Inc. “Multi-year agreements like these benefit our customers with secure pricing and provide us with running royalties that fund new innovations.”
The companies did not disclose the specific financial terms of the agreements, under which SK hynix will make a one-time payment and pay running royalties. The agreement will result in an increase in the Company’s recurring royalty revenues from SK hynix beginning in Q2 2013 because the Company reports royalties one quarter in arrears. The Company and SK hynix also agreed to dismiss the antitrust lawsuit pending in California state court. The Company is neither updating its financial guidance nor providing additional financial guidance in connection with this milestone.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Nuvectis Pharma (NVCT) files $200M mixed shelf
- enVVeno Medical (NVNO) files $100M mixed shelf
Create E-mail Alert Related Categories
Corporate News, FDA, Litigation, Management CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
